American Renal Associates Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
+0.02 (+0.17 %)
(As of 01/25/2021)
Today's Range
50-Day Range
52-Week Range
Volume9,800 shs
Average Volume106,940 shs
Market Capitalization$397.94 million
P/E RatioN/A
Dividend YieldN/A

Receive ARA News and Ratings via Email

Sign-up to receive the latest news and ratings for American Renal Associates and its competitors with MarketBeat's FREE daily newsletter.

American Renal Associates logo

About American Renal Associates

American Renal Associates Holdings, Inc. operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease. As of December 31, 2019, it operated 246 dialysis clinics in partnership with 400 nephrologist partners treating approximately 17,300 patients in 27 states and the District of Columbia. The company was founded in 1999 and is headquartered in Beverly, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

0.79 out of 5 stars

Medical Sector

2587th out of 4,434 stocks

Miscellaneous Health & Allied Services, Not Elsewhere Classified Industry

39th out of 60 stocks

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

American Renal Associates (NYSE:ARA) Frequently Asked Questions

What stocks does MarketBeat like better than American Renal Associates?

Wall Street analysts have given American Renal Associates a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but American Renal Associates wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were American Renal Associates' earnings last quarter?

American Renal Associates Holdings, Inc. (NYSE:ARA) issued its quarterly earnings data on Wednesday, November, 11th. The company reported $0.15 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.06 by $0.09. The business had revenue of $209.69 million for the quarter, compared to the consensus estimate of $211.50 million. American Renal Associates had a negative trailing twelve-month return on equity of 3.56% and a negative net margin of 2.04%.
View American Renal Associates' earnings history

Who are American Renal Associates' key executives?

American Renal Associates' management team includes the following people:
  • Mr. Joseph A. Carlucci, Co-Founder, CEO & Chairman (Age 66, Pay $1.06M)
  • Mr. Syed T. Kamal, Co-Founder, Pres & Director (Age 67, Pay $947.14k)
  • Dr. Don E. Williamson, Exec. VP & COO (Age 58, Pay $1.22M)
  • Mr. Mark C. Herbers, Interim CFO & Interim Chief Accounting Officer (Age 65)
  • Mr. Richard Pacheco CFE, AVA, MBA, VP of Admin.
  • Mr. Neal Minahan, Chief Compliance Officer & VP
  • Ms. Victoria A. Labriola Esq., M.B.A., VP, Gen. Counsel & Sec.
  • Ms. Jennifer Hood, VP of HR
  • Dr. Richard Cronin M.D., Chief Medical Officer
  • Ms. Shari Cousins R.N., C.N.N., Sr. VP of Clinical & Regulatory Services

What is Joseph Carlucci's approval rating as American Renal Associates' CEO?

62 employees have rated American Renal Associates CEO Joseph Carlucci on Glassdoor.com. Joseph Carlucci has an approval rating of 57% among American Renal Associates' employees. This puts Joseph Carlucci in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of American Renal Associates' key competitors?

What other stocks do shareholders of American Renal Associates own?

Based on aggregate information from My MarketBeat watchlists, some companies that other American Renal Associates investors own include KemPharm (KMPH), Exelixis (EXEL), Amicus Therapeutics (FOLD), Madrigal Pharmaceuticals (MDGL), Mylan (MYL), Spectrum Pharmaceuticals (SPPI), Akorn (AKRX), Fate Therapeutics (FATE), Karyopharm Therapeutics (KPTI) and Kura Oncology (KURA).

When did American Renal Associates IPO?

(ARA) raised $161 million in an initial public offering (IPO) on Thursday, April 21st 2016. The company issued 7,500,000 shares at a price of $20.00-$23.00 per share. BofA Merrill Lynch, Barclays and Goldman Sachs served as the underwriters for the IPO and Wells Fargo Securities, SunTrust Robinson Humphrey and Leerink Partners were co-managers.

What is American Renal Associates' stock symbol?

American Renal Associates trades on the New York Stock Exchange (NYSE) under the ticker symbol "ARA."

What is American Renal Associates' stock price today?

One share of ARA stock can currently be purchased for approximately $11.52.

How much money does American Renal Associates make?

American Renal Associates has a market capitalization of $397.94 million and generates $822.52 million in revenue each year. The company earns $-13,790,000.00 in net income (profit) each year or $0.26 on an earnings per share basis.

How many employees does American Renal Associates have?

American Renal Associates employs 4,977 workers across the globe.

What is American Renal Associates' official website?

The official website for American Renal Associates is www.americanrenal.com.

Where are American Renal Associates' headquarters?

American Renal Associates is headquartered at 500 CUMMINGS CENTER SUITE 6550, BEVERLY MA, 01915.

How can I contact American Renal Associates?

American Renal Associates' mailing address is 500 CUMMINGS CENTER SUITE 6550, BEVERLY MA, 01915. The company can be reached via phone at 978-922-3080 or via email at [email protected]

This page was last updated on 7/26/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.